Research records indexed for Lixisenatide
This page carries 12 of the 698 records that the literature query returned for Lixisenatide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 686 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Lixisenatide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Trial of Lixisenatide in Early Parkinson's Disease pmid:38598572 | 2024 | Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase ii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Parkinson Disease; Disease Progression; Peptides; Antiparkinson Agents; Neuroprotective Agents. |
| Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes pmid:30623563 | 2019 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Placebos; Cross-Over Studies. |
| Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial pmid:30292589 | 2018 | Research Support, Non-U.S. Gov't | other | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Kidney Diseases; Albuminuria; Diabetes Mellitus, Type 2; Peptides; Glomerular Filtration Rate. |
| Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease pmid:29175324 | 2018 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Mice, Inbred C57bl". subject headings: Neurofibrillary Tangles; Mice, Inbred C57BL; Mice, Transgenic; Encephalitis; Alzheimer Disease. |
| The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype pmid:28608285 | 2017 | Research Support, Non-U.S. Gov't | rodent | Not stated | Indexed as research support, non-u.s. gov't. study model from MeSH "Mice". subject headings: Macrophages; Diabetes Mellitus, Type 2; Insulin Resistance; Inflammation; Peptides. |
| Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial pmid:28449402 | 2017 | Comparative Study, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as comparative study, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Kidney; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Insulin; Peptides. |
| Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial pmid:27527848 | 2016 | Clinical Trial, Phase III, Multicenter Study | human trial | Not stated | Indexed as clinical trial, phase iii, multicenter study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Metformin; Blood Glucose; Peptides. |
| Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial pmid:27650977 | 2016 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Body Weight; Metformin; Insulin; Blood Glucose. |
| Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial pmid:27222510 | 2016 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose. |
| Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial pmid:27311491 | 2016 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose. |
| Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial pmid:27284114 | 2016 | Clinical Trial, Phase II, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase ii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase ii". subject headings: Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose. |
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome pmid:26630143 | 2015 | Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Not stated | Indexed as research support, non-u.s. gov't, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Cardiovascular Diseases; Angina, Unstable; Myocardial Infarction; Diabetes Mellitus, Type 2; Peptides. |
Where this page sits
Compound page: Lixisenatide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 90472060, Lixisenatide. PubChem, National Library of Medicine (2026). pubchem:90472060
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA208673. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:lixisenatide
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, obesity & metabolism (2012). pmid:22564709
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes care (2013). pmid:23628617
- Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes care (2013). pmid:23564915
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Diabetes care (2015). pmid:25887358
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes care (2016). pmid:27527848
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes care (2016). pmid:27650977
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England journal of medicine (2015). pmid:26630143
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology (2018). pmid:30292589
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC neuroscience (2012). pmid:22443187
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience (2015). pmid:26141845
- Trial of Lixisenatide in Early Parkinson's Disease. The New England journal of medicine (2024). pmid:38598572
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.